Breast cancer patients on adjuvant chemotherapy report a wide range of problems not identified by health-care staff

Breast Cancer Research and Treatment

Volumn 103, Issue 2, 2007, Pages 185-195

  Groenvold, Mogens ^a,b   Fayers, Peter M ^c,d   Petersen, Morten Aagard ^a   Sprangers, Mirjam A G ^e   Aaronson, Neil K ^f   Mouridsen, Henning T ^b  

^a BISPEBJERG HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Adjuvant therapy; Breast neoplasms; Chemotherapy; Outcomes; Quality of life

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADULT; AMENORRHEA; ANOREXIA; ANTICIPATORY NAUSEA AND VOMITING; ANXIETY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; GYNECOLOGIC DISEASE; HAIR LOSS; HEALTH CARE PERSONNEL; HEALTH PERSONNEL ATTITUDE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HOT FLUSH; HUMAN; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MENOSTASIA; MENSTRUAL IRREGULARITY; MULTIPLE CYCLE TREATMENT; NAUSEA; PAIN; PATIENT INFORMATION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEXUALITY; SIDE EFFECT; SLEEP DISORDER; STOMATITIS; SWEATING; TREATMENT OUTCOME; URINE INCONTINENCE; VAGINAL DRYNESS; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HEALTH STATUS; HUMANS; MIDDLE AGED; QUALITY OF LIFE;

EID: 34249031575     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9365-y     Document Type: Article

References (33)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
2. Chia S, Bryce C, Gelmon K (2005) The 2000 EBCTCG overview: a widening gap. Lancet 365:1665-1666
3. van Dam FSAM, Linssen ACG, Engelsman E, van Benthem J, Hanewald GJFP (1980) Life with cytostatic drugs. In: Mouridsen HT, Palshof T (eds) Breast cancer-experimental and clinical aspects. Pergamon, Oxford, pp 229-233
4. Meyerowitz BE, Watkins IK, Sparks FC (1983) Quality of life for breast cancer patients receiving adjuvant chemotherapy. Am J Nurs 83:232-234
5. Knobf MT (1986) Physical and psychologic distress associated with adjuvant chemotherapy in women with breast cancer. J Clin Oncol 4:678-684
6. Levine MN, Guyatt GH, Gent M, Pauw SD, Goodyear MD, Hryniuk WM, Arnold A, Findlay B, Skillings JR, Bramwell VH, Levin L, Bush H, Abu-Zahra H, Kotalik J (1988) Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Oncol 6:1798-1810
7. Hurny C, Bernhard J, Coates AS, Castiglione-Gertsch M, Peterson HF, Gelber RD, Forbes JF, Rudenstam CM, Simoncini E, Crivellari D, Goldhirsch A, Senn HJ (1996) Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group. Lancet 347:1279-1284
8. Groenvold M (1997) Quality of life in breast cancer adjuvant therapy: validation and pilot testing of a combination of questionnaires. Breast 6:97-107
9. Fairclough DL, Fetting JH, Cella D, Wonson W, Moinpour CM (1999) Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy. Eastern Cooperative Oncology Group (ECOG). Qual Life Res 8:723-731
10. Jacobsen PB, Hann DM, Azzarello LM, Horton J, Balducci L, Lyman GH (1999) Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manage 18:233-242
11. Shapiro CL, Recht A (2001) Side effects of adjuvant treatment of breast cancer. N Engl J Med 344:1997-2008
12. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, Mackenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651-2658
13. Land SR, Kopec JA, Yothers G, Anderson S, Day R, Tang G, Ganz PA, Fisher B, Wolmark N (2004) Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23. Breast Cancer Res Treat 86:153-164
14. Duric VM, Stockler MR, Heritier S, Boyle F, Beith J, Sullivan A, Wilcken N, Coates AS, Simes RJ (2005) Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Ann Oncol 16:1786-1794
15. Gelber RD, Bonetti M, Cole BF, Gelber S, Goldhirsch A, for the International Breast Cancer Study Group (1998) Quality of life assessment in the adjuvant setting: is it relevant? Recent Results Cancer Res 152:373-389
16. Danish Breast Cancer Cooperative Group (1989) DBCG-89. Program for treatment and follow-up of patients with primary, operable breast cancer [in Danish]. DBCG Secretariat, Copenhagen
17. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishmann SB, de Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376
18. Zigmond AS, Snaith RP (1983) The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67:361-370
19. Groenvold M, Fayers PM, Petersen MA, Mouridsen HT (2006) Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial. Breast Cancer Res Treat 98:275-284
20. Ringdal GI, Ringdal K (1993) Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses. Qual Life Res 2:129-140
21. Osoba D, Zee B, Pater J, Warr L, Kaizer L, Latreille J (1994) Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 3:353-364
22. McLachlan SA, Devins GM, Goodwin PJ (1998) Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) as a measure of psychosocial function in breast cancer patients. Eur J Cancer 34:510-517
23. Groenvold M, Klee MC, Sprangers MAG, Aaronson NK (1997) Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol 50:441-450
24. Groenvold M, Bjorner JB, Klee MC, Kreiner S (1995) Test for item bias in a quality of life questionnaire. J Clin Epidemiol 48:805-816
25. Fayers PM, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group (2001) The EORTC QLQ-C30 scoring manual, 3rd edn. European Organization for Research and Treatment of Cancer, Brussels
26. Groenvold M, Fayers PM (1998) Testing for differences in multiple quality of life dimensions: generating hypotheses from the experience of hospital staff. Qual Life Res 7:479-486
27. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF (1999) Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85:640-650
28. Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF (2000) Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18:2695-2701
29. Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, Whedon MB, Bivens S, Mitchell T, Greenberg ER, Silberfarb PM (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485-493
30. Simes RJ, Coates AS (2001) Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? J Natl Cancer Inst Monogr 30:146-152
31. Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B (2002) Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20:4628-4635
32. Bernhard J, Zahrieh D, Coates AS, Gelber RD, Castiglione-Gertsch M, Murray E, Forbes JF, Perey L, Collins J, Snyder R, Rudenstam CM, Crivellari D, Veronesi A, Thurlimann B, Fey MF, Price KN, Goldhirsch A, Hurny C (2004) Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. Br J Cancer 91:1893-1901
33. Macquart-Moulin G, Viens P, Bouscary ML, Genre D, Resbeut M, Gravis G, Camerlo J, Maraninchi D, Moatti JP (1997) Discordance between physicians' estimations and breast cancer patients' self-assessment of side-effects of chemotherapy: an issue for quality of care. Br J Cancer 76:1640-1645